Literature DB >> 23745025

Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry.

Scott V Adams1, Dennis J Ahnen, John A Baron, Peter T Campbell, Steven Gallinger, William M Grady, Loic LeMarchand, Noralane M Lindor, John D Potter, Polly A Newcomb.   

Abstract

AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC.
METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD-associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined.
RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records.
CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC.

Entities:  

Keywords:  Cancer survival; Colorectal cancer; Inflammation; Inflammatory bowel disease; Outcomes research

Mesh:

Year:  2013        PMID: 23745025      PMCID: PMC3671075          DOI: 10.3748/wjg.v19.i21.3241

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.

Authors:  P D Collins; C Mpofu; A J Watson; J M Rhodes
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

3.  Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.

Authors:  Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich
Journal:  Gut       Date:  2010-11-04       Impact factor: 23.059

4.  Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study.

Authors:  Ane B Jensen; Mette Larsen; Mette Gislum; Mette V Skriver; Peter Jepsen; Bente Nørgaard; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

5.  Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.

Authors:  Fernando S Velayos; Jonathan P Terdiman; Judith M Walsh
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

6.  Survival after colorectal cancer in patients with Crohn's disease: A nationwide population-based Danish follow-up study.

Authors:  Mette Larsen; Hanne Mose; Mette Gislum; Mette V Skriver; Peter Jepsen; Bente Nørgård; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2006-10-13       Impact factor: 10.864

7.  Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study.

Authors:  Amit Mahipal; Kristin E Anderson; Paul J Limburg; Aaron R Folsom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

8.  Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.

Authors:  Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Charles S Fuchs
Journal:  Gastroenterology       Date:  2010-11-27       Impact factor: 22.682

Review 9.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

Authors:  Enrico Flossmann; Peter M Rothwell
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

10.  Colorectal cancer prognosis among patients with inflammatory bowel disease.

Authors:  Thierry Delaunoit; Paul J Limburg; Richard M Goldberg; James F Lymp; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

View more
  6 in total

1.  The Aryl Hydrocarbon Receptor is a Repressor of Inflammation-associated Colorectal Tumorigenesis in Mouse.

Authors:  Carol J Díaz-Díaz; Sean M Ronnekleiv-Kelly; Manabu Nukaya; Peter G Geiger; Silvia Balbo; Romel Dator; Bryant W Megna; Patrick R Carney; Christopher A Bradfield; Gregory D Kennedy
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

2.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

3.  Neuropeptide Y (NPY) promotes inflammation-induced tumorigenesis by enhancing epithelial cell proliferation.

Authors:  Sabrina Jeppsson; Shanthi Srinivasan; Bindu Chandrasekharan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-17       Impact factor: 4.052

Review 4.  Inflammatory bowel disease associated neoplasia: A surgeon's perspective.

Authors:  Azah A Althumairi; Mark G Lazarev; Susan L Gearhart
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

5.  Inflammatory Bowel Disease Adversely Impacts Colorectal Cancer Surgery Short-term Outcomes and Health-Care Resource Utilization.

Authors:  Mitchell Ramsey; Somashekar G Krishna; Peter P Stanich; Syed Husain; Edward J Levine; Darwin Conwell; Alice Hinton; Cheng Zhang
Journal:  Clin Transl Gastroenterol       Date:  2017-11-30       Impact factor: 4.488

Review 6.  A Systematic Review and Meta-Analysis on the Association between Inflammatory Bowel Disease Family History and Colorectal Cancer.

Authors:  Hadis Najafimehr; Hamid Asadzadeh Aghdaei; Mohamad Amin Pourhoseingholi; Hamid Mohaghegh Shalmani; Amir Vahedian-Azimi; Matthew Kroh; Mohammad Reza Zali; Amirhossein Sahebkar
Journal:  Gastroenterol Res Pract       Date:  2021-10-23       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.